Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) has scheduled a video webcast for May 9, 2025, from 10:00 a.m. to 11:30 a.m. ET. During this event, the clinical-stage biopharmaceutical company will:

• Present its Q1 2025 financial results
• Unveil a new oral development candidate targeting an undrugged target for autoimmune and rheumatic diseases
• Review highlights and upcoming milestones of its immunology pipeline

The webcast will be accessible through registration and available for replay on the company's website under the Investors section.

Positive

• New oral drug candidate announcement for autoimmune diseases pipeline expansion

Negative

• None.

Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. 

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Availability of Other Information About Kymera Therapeutics
For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor and Media Contact: 
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300 

FAQ

What will Kymera Therapeutics (KYMR) announce in their May 9, 2025 webcast?

Kymera will announce Q1 2025 financial results and reveal a new oral development candidate for autoimmune and rheumatic diseases, along with immunology pipeline updates.

How can investors access Kymera Therapeutics' (KYMR) Q1 2025 earnings webcast?

Investors can access the webcast by registering through the provided link or visiting the 'News and Events' section in the Investors area of www.kymeratx.com.

What is the focus of Kymera Therapeutics' (KYMR) new drug development program?

The new program focuses on an undrugged target for multiple autoimmune and rheumatic diseases, utilizing oral small molecule degrader medicines.

What time is Kymera Therapeutics' (KYMR) Q1 2025 earnings call?

The video webcast is scheduled for Friday, May 9, 2025, from 10:00 a.m. to 11:30 a.m. ET.